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Abstract
 
Chronic myelogenous leukemia (CML) is characterized by the presence of the chimeric
p210
 
bcr/abl 
 
oncoprotein that shows elevated and constitutive protein tyrosine kinase activity relative
to the normal c-abl tyrosine kinase. Although several p210
 
bcr/abl 
 
substrates have been identified,
their relevance in the pathogenesis of the disease is unclear. We have identified a family of proteins,
Dok (downstream of tyrosine kinase), coexpressed in hematopoietic progenitor cells. Members
of this family such as p62
 
dok 
 
(Dok-1) and p56
 
dok-2 
 
(Dok-2) associate with the p120 rasGTPase-
activating protein (rasGAP) upon phosphorylation by p210
 
bcr/abl 
 
as well as receptor and nonreceptor
tyrosine kinases. Here, we report the generation and characterization of single and double 
 
Dok-1
 
or 
 
Dok-2
 
 knockout (KO) mutants. Single KO mice displayed normal steady-state hematopoiesis.
By contrast, concomitant 
 
Dok-1
 
 and 
 
Dok-2
 
 inactivation resulted in aberrant hemopoiesis and
Ras/MAP kinase activation. Strikingly, all 
 
Dok-1
 
/
 
Dok-2
 
 double KO mutants spontaneously
developed transplantable CML-like myeloproliferative disease due to increased cellular prolif-
eration and reduced apoptosis. Furthermore, 
 
Dok-1
 
 or 
 
Dok-2
 
 inactivation markedly accelerated
leukemia and blastic crisis onset in 
 
Tec-p210
 
bcr/abl 
 
transgenic mice known to develop, after long
latency, a myeloproliferative disorder resembling human CML. These findings unravel the crit-
ical and unexpected role of Dok-1 and Dok-2 in tumor suppression and control of the hematopoi-
etic compartment homeostasis.
Key words: cell proliferation • apoptosis • knockout • CML leukemogenesis • 
signal transduction
 
Introduction
 
Chronic myelogenous leukemia (CML) is a clonal disorder
of the hematopoietic cells characterized by the presence of
the Philadelphia chromosome (Ph
 

 
), which is the result of
a chromosomal translocation between the BCR gene on
chromosome 22 and the ABL gene on chromosome 9 (1,
2). A bcr-abl chimeric protein originates from this translo-
cation. Its p210 form, which is the causative mutation
found in 95% of cases of CML, has elevated tyrosine kinase
activity and exists exclusively in cytoplasm compared with
endogenous c-ABL (1, 2). Two phases of the disease have
been characterized: (a) a chronic phase with an average
span of 3–5 yr during which the Ph
 
 
 
cells populate the entire
intermediate and late hematopoietic maturational compart-
ments, and (b) an acute malignant and fatal stage known as
blast crisis when the leukemic cells acquire additional genetic
changes, lose their ability to differentiate and mature, and
acquire the ability to infiltrate and colonize other organs (1,
2). Inhibition of p210
 
bcr/abl 
 
activity by selective drugs such
as STI571 leads to disease remission, making CML a para-
digmatic example of targeted cancer therapy (3). However,
patients do relapse upon STI571 treatment, underscoring
the need to identify critical downstream events in the
p210
 
bcr/abl 
 
signaling cascade. Furthermore, the genetics of
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blastic crisis transformation is poorly understood. 
 
p62
 
dok
 
(Dok-1) was cloned as a major phosphorylation substrate of
the p210
 
bcr/abl 
 
oncoprotein in Ph
 
 
 
CML blasts, as well as a
major substrate of many tyrosine kinases (4, 5). Soon after,
additional members of the family (6-9) have been identified.
These proteins resemble docking proteins in their structure
because they contain PH and PTB domains as well as multi-
ple binding motifs for SH2 and SH3 domains. Three of
them (Dok-1–3) are differentially expressed in the hemopoi-
etic compartment, coexpressed in the hemopoietic progeni-
tors, and aberrantly phosphorylated by p210
 
bcr/abl 
 
(4, 6, 7, 9).
Several recent reports implicate Dok proteins in the negative
regulation of signaling pathways activated by tyrosine kinases
(9-14). Unlike Dok-3–5, Dok-1 and Dok-2 are able to asso-
ciate with rasGAP when phosphorylated, suggesting that
they may serve critical, but possibly redundant, functions (6,
9). Therefore, to determine the role of DOK as p210
 
bcr/abl
 
substrates in hematopoiesis and CML pathogenesis, we stud-
ied in vivo in the mouse the effect of combined inactivation
of DOK family members. Here, we unravel the key tumor
suppressive role of Dok-1 and Dok-2 in the hemopoietic
compartment and their importance in CML pathogenesis.
 
Materials and Methods
 
Targeting Vector and Generation of Dok-2
 
 
 
Embryonic Stem
Cells.
 
A 129/Sv mouse genomic library (Stratagene) was
screened with a probe containing murine 
 
Dok-2
 
 exon 1. Exon/
intron boundaries of the isolated 
 
Dok-2
 
 genomic clones were de-
termined by restriction enzyme mapping, DNA sequencing, and
PCR. To generate the targeting construct, a 2.7-Kb EcoRI–SacI
 
Dok-2
 
 genomic fragment (5
 
 
 
arm
 
)
 
 and a 4.5-Kb XhoI–HindIII
 
Dok-2
 
 genomic fragment (3
 
 
 
arm
 
)
 
 were cloned into the pPNT
(13). The targeting construct was linearized with NotI and elec-
troporated into CJ7 embryonic stem cells. Transfectants were se-
lected in 350 
 

 
g/ml G418 and 2 
 

 
M gancyclovir and expanded
for Southern blot analysis using a 5
 
 
 
probe (see Fig. S1 A below).
 
Generation of Dok-2
 

 
, Double KO (DKO), and Tec-p210
 
bcr/abl
 
/
Dok-1/Dok-2 Compound Mutants.
 
Chimeric mice and F1 off-
spring were produced as described previously (13). Chimeric
males were then mated with 129/Sv females (The Jackson Labo-
ratory) to obtain 
 
Dok-2
 
 mutants in a 129/Sv background. 
 
Dok-
1
 

 
/
 
 
 
mice (13) and 
 
Tec-p210
 
bcr/abl 
 
transgenic mice (TM; references
15 and 16) have been described. 
 
Dok-1
 

 
/
 

 
/
 
Dok-2
 

 
/
 
 
 
mice were
obtained by interbreeding 
 
Dok-1
 

 
/
 
 
 
mice with 
 
Dok-2
 

 
/
 
 
 
mice
both in 129/Sv background. To obtain 
 
Tec-p210
 
bcr/abl
 
/
 
Dok-1
 
/
 
Dok-2
 
 compound mice, 
 
Tec-p210
 
bcr/abl 
 
TM were at first crossed
with 
 
Dok-1
 

 
/
 
 
 
mice (129/Sv) or 
 
Dok-2
 

 
/
 
 
 
mice (129/Sv). F1
offspring were then mated with each other to get 
 
Tec-p210
 
bcr/abl
 
/
Dok null mice and to balance the genetic background. All mice
studies were approved by The Institutional Animal Care and Use
Committee of Memorial Sloan-Kettering Cancer Center.
 
Follow-up Design and Leukemia Diagnosis.
 
Mice were moni-
tored monthly by peripheral blood (PB) counts and smears (bi-
weekly in the case of 
 
Tec-p210
 
bcr/abl
 
/
 
Dok-1/Dok-2
 
 compound
mutants and BM transplantation). Diagnosis of leukemia was
made on the criteria that two consecutive white blood cell counts
are 
 

 
20 
 
 
 
10
 
3
 
/
 

 
l. Autopsies were performed on dead or mori-
bund animals as described previously (17). For B220 or CD3 de-
tection, immunohistochemistry was performed on representative
sections using anti–mouse B220 monoclonal antibody (RA3-
6B2; BD Biosciences) or a rabbit anti-CD3 polyclonal antibody
(DakoCytomation) according to the manufacturer’s instructions.
 
BM Transplantation.
 
2 
 
 
 
10
 
6 
 
BM cells from WT or 
 
Dok-1
 

 
/
 

 
/
 
Dok-2
 

 
/
 
 
 
mutant mice were injected via tail vein into lethally
irradiated (920 rads) 129/Sv WT mice (6-wk-old female). Recip-
ient mice were monitored and scored positive for disease accord-
ing to criteria mentioned in the legend to Fig. S2 (see below). 
 
Western Blot and Flow Cytometric Analysis.
 
These analyses
were performed as described previously (13, 18). For Western
blot analysis, we used a rabbit polyclonal anti–Dok-R/Dok2 an-
tibody (Upstate Cell Signaling) to detect Dok-2 protein. To de-
tect Erk 2 protein, we used a polyclonal anti–Erk 2 antibody
(Santa Cruz Biotechnology, Inc.). For flow cytometry, we used
the following conjugated antibodies: anti–c-Kit, anti–Sca-1, anti–
Mac-1, anti–Gr-1, anti-F4/80, anti-CD3 complex, anti-B220,
anti-CD4, and anti-CD8a. Anti-F4/80 was obtained from Cal-
tag. All other antibodies were from BD Biosciences. Flow cy-
tometry was performed using a FACScan (Becton Dickinson).
The data were analyzed using FlowJo software (Tree Star).
 
Ras GTPase Activation Assay. 
 
Activation of Ras was mea-
sured using GST-RBD (Ras-binding domain of Raf [RBD]) pull
down assays (19). The underlying premise of this assay is that the
RBD binds only to GTP-bound Ras proteins. Mac-1
 
 
 
cells were
isolated from freshly isolated BM cells using CD11b Microbeads
(Miltenyi Biotec). Purity (
 

 
90%) was confirmed by flow cytom-
etry. Mac-1
 
 
 
cells were incubated in RPMI/0.1% FCS for 3 h,
and then stimulated with 10 ng/ml GM-CSF for 10 min at 37
 

 
C.
Cells were then lysed in 25 mM Hepes, pH 7.5, 150 mM NaCl,
1% NP-40, 10% glycerol, 25 mM NaF, 10 mM MgCl
 
2
 
, 1 mM
EDTA, 2.5 mM sodium deoxycholic, and 1 mM Na
 
3
 
VO
 
4 
 
plus
protease inhibitors. An equal amount of cell lysates was incubated
with GST-RBD coupled to glutathione beads. Bead-associated
Ras (GTP-bound Ras) and total Ras in cell lysates were detected
by Western blotting with an anti–pan-Ras antibody (Transduc-
tion Laboratories). GM-CSF–induced Ras activation is measured
by normalizing the amount of GTP-bound Ras to the total
amount of Ras in cell lysates.
 
Proliferation, Apoptosis, and In Vitro Colony-forming Assay.
 
BM
cells were flushed from murine femurs and tibiae. 2 
 
 
 
10
 
4 
 
cells were
plated in MethoCult M3434 (StemCell Technologies Inc.). Colo-
nies were counted on days 2 (CFU-E), 7 (CFU-GM and BFU-E),
and 13 (CFU-GEMM). For proliferation assay of collected cells
from in vitro colony-forming assay, 2 
 
 
 
10
 
4 
 
BM cells were plated in
MethoCult M3234 with 20 ng/ml IL-3, 50 ng/ml G-CSF, and 20
ng/ml GM-CSF. At day 7, cells were collected from methylcellu-
lose and washed by RPMI/10% FCS and counted. 2.5 
 
 
 
10
 
4 
 
cells
were cultured without growth factor for 20 h. [
 
3
 
H]thymidine was
then added for 4 h. For proliferation assays of BM cells, contaminat-
ing erythrocytes were removed by hypotonic lysis. Mac-1
 
 
 
cells
were isolated using CD11b Microbeads (Miltenyi Biotec). Purity
(
 

 
90%) was confirmed by flow cytometry. Cells were treated with
10 ng/ml IL-3, 10 ng/ml stem cell factor (SCF), or 10 ng/ml GM-
CSF for 42 h. [
 
3
 
H]thymidine was then added for 6 h. For apoptosis
analysis, BM cells were cultured as described above. After 48 h, cells
were harvested and incubated with anti-CD16/32 to block nonspe-
cific binding. Cells were then stained with anti–Mac-1–APC and
annexin V (BD Biosciences) according to the manufacturer’s in-
structions. The percentage of apoptotic cells was determined by
FACS analysis (FACSCalibur; Becton Dickinson).
 
Spectral Karyotyping Analysis.
 
BM cells from DKO mice were
cultured in RPMI 1640/10% FCS with 6 ng/ml IL-3, 10 ng/ml
IL-6, 100 ng/ml SCF, and 10 ng/ml BrdU for 18 h. The cells
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were then prepared for cytogenetic analysis performed using a
mouse SkyPaint Kit (Applied Spectral Imaging) according to the
manufacturer’s instructions.
 
Online Supplemental Material.
 
Fig. S1 shows targeted disrup-
tion of the 
 
Dok-2
 
 gene. Fig. S2 shows results of adoptive transfer
of BM cells from DKO mice with myeloproliferative disease
(MPD). Fig. S3 shows FACS analysis of BM and spleen cells
from leukemic 
 
Tec-p210
 
bcr/abl
 
, Tec-p210
 
bcr/abl
 
/Dok-1
 

 
/
 

 
, and 
 
Tec-
p210bcr/abl/Dok-2/ mice and survival curves of these compound
mutants. Table S1 shows the data of PB cell count. Figs. S1–S3
and Table S1 are available at http://www.jem.org/cgi/content/
full/jem.20041306/DC1.
Results and Discussion
We inactivated the Dok-2 gene in the mouse and crossed
Dok-2 mutants with Dok-1/ mice that we described pre-
viously (13). As in the case of Dok-1–targeted disruption,
Dok-2/ mutants were born following mendelian frequen-
Figure 1. MPD in Dok-1//
Dok-2/ mutants. (A) MPD-
free survival curve of WT, Dok-
1/, Dok-2/ single mutants,
and Dok-1//Dok-2/ mutant
(DKO) mice. (B) Time course of
white blood cell counts of WT
(black line) and Dok-1//Dok-
2/ mutants (red line). (C)
Splenomegaly in Dok-1//Dok-
2/ diseased mutants. Spleen
from 1-yr-old WT (left) and
Dok-1//Dok-2/ mice (right).
(D) Morphology of PB, BM, and
spleen cells from 1-yr-old WT
and Dok-1//Dok-2/ mutants
(DKO). The smears of PB and
cytospins of BM and spleen were
stained with Wright-Giemsa
stain. Original magnifications:
100 for PB and 400 for BM and
spleen. Differentiated granulo-
cytes (arrowheads) are seen in
spleen cytospin from Dok-1//
Dok-2/ mutant (DKO). (E)
High magnification (400) of PB
from Dok-1//Dok-2/ mu-
tant. Arrows indicate differenti-
ated granulocytes and arrow-
head indicates blast cell. (F) Flow
cytometric analysis of PB from
a Dok-1//Dok-2/ mutant
(DKO) and WT littermate. PB
cells were double stained with
anti–c-Kit–PE and anti–Sca-1–
FITC. Percentages of positive
cells are shown in each quadrant.
(G) Flow cytometric analysis of
splenocytes from a Dok-1//
Dok-2/ (DKO) mutant and WT
littermate. (H) Absolute numbers
of total, Mac-1, Mac-1/Gr-1,
Mac-1/F4/80, CD3, and
B220 cells from 1-yr-old WT
(white bars) and DKO mutant
(black bars). Spleens from three
WT and three DKO mutants
were analyzed by flow cytome-
try. The number of positive cells
for each marker was calculated.
Means and SD are indicated. (I)
In vitro colony-forming assay
performed with BM cells isolated
from a 1-yr-old WT (white bar)
and diseased DOK mutant (black
bar). P-value is also shown.
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cies. Postmortem pathological analysis and monthly flow
cytometric and morphological assessments of the various
hematopoietic organs from Dok-2/ mutants revealed nor-
mal steady-state hematopoiesis and organogenesis (unpub-
lished data). Analysis of Dok-1 and Dok-2 protein expres-
sion in the various hematopoietic organs from Dok-1/ and
Dok-2/ mutants, respectively, did not reveal compen-
satory up-regulation of the remaining Dok protein (Fig.
S1 E, available at http://www.jem.org/cgi/content/full/
jem.20041306/DC1). Furthermore, in standard colony-
forming assays in methylcellulose, BM progenitors from
Dok-2/ mutants yielded numbers of erythroid and mye-
loid colonies comparable to WT sex- and age-matched lit-
termates (Fig. S1 F). Although myeloid differentiation was
overall normal in Dok-2/ mice, we did observe a consis-
tent defect in the activation of Dok-2/ mature granulocyte
upon TPA treatment (unpublished data). Nevertheless,
Dok-2/ mice did not display an increase incidence of
spontaneous infections. The fact that both Dok-1 and Dok-2
KO mutants displayed normal steady-state hemopoiesis sug-
gested that they may exert redundant function. 
Therefore, we generated DKO mutants. These mutants
were also developmentally normal (as revealed by patho-
logical analysis of all organs; unpublished data) and fertile.
However, monthly postmortem pathological, flow cyto-
metric, and morphological assessments of the various he-
matopoietic organs from DKO mutants unraveled striking
differences with respect to the Dok-1 and Dok-2 single KO
mutants. In fact, DKO mutants developed at complete
penetrance a CML-like MPD at 10–12 mo of age (Fig. 1
A; refer to Materials and Methods). DKO displayed a pro-
gressive increase in white blood cell counts in the PB after
4 mo of age (Fig. 1 B and Table S1, which is available
at http://www.jem.org/cgi/content/full/jem.20041306/
DC1; at 4 mo: WT [n 	 6] 9,800 
 2,078, DKO [n 	 6]
9,725 
 3,007; at 8 mo: WT [n 	 6] 10,033 
 1,286,
DKO [n 	 7] 15,575 
 2,326; at 12 mo: WT [n 	 6]
9,200 
 3,268, DKO [n 	 8] 24,180 
 4,540). At leuke-
mia onset, DKO mice invariably displayed a marked sple-
nomegaly (Fig. 1 C; WT [n 	 3] 0.051 
 0.005 g, DKO
[n 	 3] 0.081 
 0.02 g) as well as PB and BM hypercellu-
larity (Fig. 1 D and Table S1). BM and spleen were both
predominantly infiltrated by myeloid cells that retained the
ability to terminally differentiate (Fig. 1 D). Automated and
differential counts in the PB revealed a marked leukocytosis
caused by an increase in the number of neutrophils and
monocytes (Table S1). Interestingly, erythrocytes and plate-
lets number counts remained relatively normal at this
stage (Table S1). The increase in PB cellularity was accom-
panied by the appearance of undifferentiated blasts in the
Figure 2. Analysis of preleukemic Dok-1//Dok-2/
mutants. (A) In vitro colony-forming assay performed
with BM cells isolated from a WT (white bar) and a
Dok-1//Dok-2/ mutant (DKO; black bar) at 4 mo
of age. P-value is also shown. (B) [3H]thymidine incorpo-
ration analysis of proliferative response of cells collected
from in vitro colony assay of BM cells from 2-mo-old
WT, Dok-1/, Dok-2/, and DKO mice. (C) Prolif-
erative response determined by [3H]thymidine incor-
poration of Mac-1 BM cells upon IL-3, GM-CSF,
and SCF stimulation. (D) Apoptotic response to
growth factor deprivation in BM cells. Cell death was
analyzed by annexin V staining of WT (white bar) and
Dok-1//Dok-2/ (DKO; black bar) Mac-1 BM
cells. (E) GM-CSF–induced Ras activation of Mac-1
BM cells isolated from 4-mo-old WT, Dok-1/, Dok-
2/, and DKO mice. A representative Western blot
from three experiments is shown. Very low amounts of
Ras-GTP were detected in serum-starved cells before
GM-CSF treatment. (F) Relative Ras activity in the
above cells treated with GM-CSF is quantified by the
ratio of GTP-bound Ras over total Ras. The value of
WT BM cells was set as 1 and the ratios of other types
of BM cells were calculated correspondingly. (G) Levels
of ERK 1/2 phosphorylation upon (lanes 3 and 4) or in
the absence (lanes 1 and 2) of GM-CSF stimulation in
BM cells from WT (lanes 1 and 3) and Dok-1//Dok-
2/ (lanes 2 and 4) mice.
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PB (Fig. 1 E and Table S1). Flow cytometric analysis of
PB, BM, and spleen confirmed the expansion of the differ-
entiated myeloid compartment (increase in the percentage
of Mac-1, Gr-1, and Mac-1 F4/80 cells with a con-
comitant decrease in the percentage of B220 [B cell] and
CD3 [T cell] cells) as well as the presence of undifferenti-
ated cells in the PB (Sca-1 cells: WT [n 	 4] 6.5 
 4.3%,
DKO [n 	 4] 13.5 
 2.9%; Fig. 1, F–H). Colony-forming
assays in methylcellulose from BM cells of DKO diseased
mice revealed the expansion of myeloid progenitors (Fig. 1
I). A higher number of progenitors (CFU-GM) from BM
cells of DKO mice was already observed in the preleuke-
mic phase (4 mo of age; Fig. 2 A). Next, we assessed
whether the MPD was transplantable (refer to Materials
and Methods). To this end, BM cells from disease DKO
mice or WT controls were transplanted into lethally irradi-
ated recipient mice. Five out of the seven recipient mice
that were transplanted with cells from DKO mice devel-
oped overt disease (Fig. S2 A) with splenomegaly (Fig. S2
B) and a marked increase in the percentage of Mac-1
Gr-1 cells in the spleen (Fig. S2 C). Thus, at onset, the
MPD is fully transplantable, hence demonstrating the cell
autonomy of the disorder. We also studied whether the
MPD was the result of a clonal evolution by performing
spectral karyotyping analysis (refer to Materials and Meth-
ods) on BM cells from diseased DKO mice. At least 12
metaphase cells per mouse (n 	 4) were analyzed and no
karyological abnormalities were found.
Next, we investigated the molecular and biological con-
sequences of concomitant Dok-1 and Dok-2 inactivation in
cells from DKO mutants before leukemia onset (2–4-mo-
old mice). Myeloid BM cells from DKO mice displayed in-
creased proliferative potential upon IL-3, GM-CSF, and
SCF stimulation (Fig. 2 C). Furthermore, DKO myeloid
cells collected from in vitro colony-forming assays dis-
played increased proliferative potential even in the absence
of growth factor (Fig. 2 B). Furthermore, Dok-1 and Dok-2
inactivation protected myeloid BM cells from growth fac-
tor deprivation–induced cell death (Fig. 2 D).
As Dok-1 and Dok-2 can act as negative Ras regulator
(12–14), we tested the level of Ras activation upon GM-
CSF stimulation in Mac-1 BM cells, which are known to
normally coexpress these two proteins, from single and
DKO mice and WT mice. DKO cells indeed displayed ele-
vated levels of Ras activation (Fig. 2, E and F). Further-
more, we observed a marked elevation of MAP kinase (p44
and p42 Erk) activation upon GM-CSF stimulation in the
BM from DKO mutants (Fig. 2 G). Thus, the concomitant
inactivation of Dok-1 and Dok-2 causes profound biological
and molecular outcomes, which result in overt disease at
full penetrance.
On the basis of what we observed in DKO mutants,
Dok-1 and Dok-2 may therefore oppose the leukemogenic
potential of p210bcr/abl. To test this hypothesis genetically in
vivo, we made use of a Tec-p210bcr/abl transgenic model. Tec-
p210bcr/abl TM are faithful animal models of CML as they
develop a chronic leukemic phase after a long latency, fol-
lowed by an acute terminal phase that is reminiscent of a
CML blastic crisis with appearance of blasts in the PB and
organ infiltration (15, 16). Therefore, we crossed Tec-
Figure 3. Leukemia onset and phenotype of Tec-
p210bcr/abl/Dok-1/Dok-2 compound mutants. (A) Leuke-
mia-free survival curves of Tec-p210bcr/abl()/Dok-1
mutants. P-value is also indicated. (B) Leukemia-free
survival curves of Tec-p210bcr/abl()/Dok-2 mutants.
P-value is also indicated. (C) Morphology of PB cells
from a Tec-p210bcr/abl()/Dok-2/ mouse during the
blast crisis. Blasts (arrowheads) are indicated. Original
magnification of 200. (D) Magnification (1,000) of
boxed region in C. Blast cell is indicated by arrowhead.
(E) Hematoxylin and eosin staining of lung from a Tec-
p210bcr/abl()/Dok-2/ mouse killed during the blast
crisis. Alveolar interstitial spaces are infiltrated by accu-
mulation of erythrocytes (arrowheads) and invasion of
both myeloid blasts and differentiated cells. Original
magnification of 100. (F) High magnification of E.
Many differentiated granulocytes are seen. Original
magnification of 400. (G) Hematoxylin and eosin stain-
ing of an invasive lymphoma in the ileum in a Tec-
p210bcr/abl()/Dok-2/ mouse. A monomorphic infil-
trate of lymphocytic cells (indicated by the dashed oval)
with hyperchromatic and dysplastic nuclei is identified
under the mucosa (arrowheads). These cells are invad-
ing beyond the muscularis mucosa into the submucosa
(stars). Cobblet cells (arrow) are seen. Original magnifi-
cation of 200. (H and I) Immunohistochemical staining
of the lymphoma shown in G using anti-B220 antibody
(H; for B cell identification) and anti-CD3 antibody (I; for
T cell identification). Original magnification of 200. (J)
Incidence of invasive lymphoma in Tec-p210bcr/abl(), Tec-
p210bcr/abl()/Dok-1/, and Tec-p210bcr/abl()/Dok-2/
mice.
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p210bcr/abl TM with Dok-1/ and Dok-2/ mutants and as-
sessed whether their inactivation would impact on the biol-
ogy of the disease. Inactivation of either Dok-1 or Dok-2
accelerated chronic phase onset in compound mutants (Fig.
3, A and B). By contrast, the distinctive features of the
chronic phase in Tec-p210bcr/abl TM were not perturbed by
Dok-1 or Dok-2 inactivation as revealed by comparable
flow cytometric and morphological profiles of the major
hematopoietic organs (Fig. S3 A and unpublished data).
Furthermore, and importantly, Dok-1 or Dok-2 inactiva-
tion accelerated the onset of the fatal blastic phase of the
disease resulting in a marked reduction in overall survival in
the compound mutants (Fig. 3, C–F, and Fig. S2, B and C;
mean survival of Dok-1 crosses: Tec-p210bcr/abl/WT: 324.7 

50.0 d; Tec-p210bcr/abl/Dok-1/: 307.4 
 67.1 d; Tec-
p210bcr/abl/Dok-1/: 284.9 
 65.4 d; mean survival of
Dok-2 crosses: Tec-p210bcr/abl/WT: 320.9 
 54.8 d; Tec-
p210bcr/abl/Dok-2/: 282.7 
 96.0 d; p210bcr/abl/Dok-2/:
270.5 
 48.7 d) as well as in shortening of the chronic
phase (Dok-1 crosses: Tec-p210bcr/abl/WT [n 	 10] 84.6 

46.3 d; Tec-p210bcr/abl/Dok-1/ [n 	 21] 78.2 
 47.5 d;
Tec-p210bcr/abl/Dok-1/ [n 	 9] 78.2 
 44.1 d; Dok-2
crosses: Tec-p210bcr/abl/WT [n 	 8] 83.8 
 31.1 d; Tec-
p210bcr/abl/Dok-2/ [n 	 13] 76.9 
 39.6 d; Tec-p210bcr/abl/
Dok-2/ [n 	 9] 70.0 
 27.7 d). Postmortem analysis of
compound mutants in various genotypes did not reveal
qualitative differences in the biology and cellularity of the
blast crisis. In mice from all genotypes, blasts and myeloid
differentiating cells (e.g., neutrophils) were found to infil-
trate solid organs such as the lung (Fig. 3, C–F). By con-
trast, a major difference was observed in analyzing the
intestinal tract of the various compound mutants. Approxi-
mately 25% of the Tec-p210bcr/abl/Dok-2/ mutants ana-
lyzed were found to develop an aggressive and infiltrating
lymphoma of the small intestine of B cell origin (Fig. 3,
G–J). By contrast, this malignancy was not observed in the
Tec-p210bcr/abl/Dok-1/ mutants analyzed (Fig. 3 J).
Our analysis leads to three major conclusions: (a) Dok-1
and Dok-2 play a pivotal cooperative role in the control of
the homeostasis of the hematopoietic compartment and in
tumor suppression, as their combined loss triggers a CML-
like MPD at complete penetrance; (b) Dok-1 and Dok-2
negatively regulate Ras and MAP kinase activation, and
their loss leads to the hematopoietic cells’ proliferative and
survival advantage in the presence or the absence of
growth factors, respectively; and (c) Dok-1 and Dok-2 op-
pose p210bcr/abl-driven leukemogenesis and lymphomagene-
sis. Therefore, Dok-1 and Dok-2 functional loss may exac-
erbate and accelerate the natural history of the human disease.
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